03Dec 2022
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition

The study evaluated the impact of CDK4/6 inhibition by palbociclib in 28 MPM cell lines including 19 patient‐derived ones, using various approaches including RNA‐sequencing. This was associated with high p16INK4A (CDKN2A) levels that accompany RB1 defects or inactivation, or (unexpectedly) CCNE1 overexpression in the presence of wild‐type RB1. Its absence in some highly proliferative MPMs has been linked to very high p16 (CDKN2A) expression, which was also observed in public datasets in tumours from short-survival patients. The study supports the evaluation of CDK4/6 inhibitors for MPM treatment, in monotherapy or combination therapy.

  • #oncology

Like

Save

Share